Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers

NCT04752358 is registered in ClinicalTrials.gov with Adaptimmune as lead sponsor.

NCT NCT04752358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04752358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
Lead sponsor
Adaptimmune
Phase
Phase 2
Overall status
Terminated
Start date
September 15, 2021
Completion date
December 15, 2023
Enrollment
3 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, esophagogastric junction cancer